For example, although angiotensin-converting enzyme (ACE) inhibitors have been considered a standard of care for hypertension in diabetic patients, with no known effects on endothelial fenestrations [94], sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently been identified as a promising therapy to slow DN progression [95]. The gene discussed is SLC5A2; the disease is hypertensive disorder.